Agaplesion Markus Krankenhaus

A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE) (2021) Loibl S, Schmidt M, Luebbe K, Decker T, Thill M, Bauer L, Mueller V, et al. Conference contribution Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie: 17. Internationale St.-Gallen-Konsensuskonferenz vor dem Hintergrund deutscher Therapieempfehlungen diskutiert (2021) Schneeweiss A, Huober J, Brucker SY, Budach W, Denkert C, Fasching P, Haidinger R, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer (2021) Lüftner D, Hartkopf AD, Lux MP, Overkamp F, Tesch H, Titzmann A, Pöschke P, et al. Journal article, Review article Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Aktualisierte S3-Leitlinie Colitis ulcerosa-Living Guideline-August 2020-AWMF-Registriernummer: 021-009 (2020) Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengieβer K, et al. Journal article Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) de Gregorio A, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article